로그인 회원가입
icon_bulk_order대량 주문 Acrobiosystems for English
0
장바구니가 비어 있습니다
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > IGF-I R

IGF-I R

요약

Name:Insulin-like growth factor I receptor
Target Synonym:IGF-I receptor,IGF1R,Insulin Like Growth Factor 1 Receptor,Insulin-Like Growth Factor 1 Receptor,Insulin-Like Growth Factor I Receptor,Soluble IGF1R Variant 1,Soluble IGF1R Variant 2,CD221 Antigen,CD221,IGFIR,JTK13,IGFR,Receptor, IGF Type 1,MGC18216
Number of Launched Drugs:6
Number of Drugs in Clinical Trials:26
Lastest Research Phase:Approved

제품 리스트 구매

Synonym Name

IGF1R,IGFR,JTK13,CD221,MGC142170,MGC142172,MGC18216

Background

The Insulin-like Growth Factor 1 Receptor (IGF1) is also known as CD221, JTK13. and is a transmembrane receptor that is activated by IGF-1 and by the related growth factor IGF-2. It belongs to the large class of tyrosine kinase receptors. This receptor mediates the effects of IGF-1, which is a polypeptide protein hormone similar in molecular structure to insulin. IGF1R is make up of two alpha subunits and two beta subunits ,the Both the α and β subunits are synthesized from a single mRNA precursor. The precursor is then glycosylated, proteolytically cleaved, and crosslinked by cysteine bonds to form a functional transmembrane αβ chain.The α chains are located extracellularly while the β subunit spans the membrane and are responsible for intracellular signal transduction upon ligand stimulation. IGF1R have a binding site for ATP, which is used to provide the phosphates for autophosphorylation. There is a 60% homology between IGF1R and the insulin receptor. In response to ligand binding, the α chains induce the tyrosine autophosphorylation of the β chains. This event triggers a cascade of intracellular signaling that, while somewhat cell type specific, often promotes cell survival and cell proliferation.

Clinical and Translational Updates

공개 약품 정보

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Mecasermin (Astellas/OrphanPacific) Approved Astellas Pharma Inc Somazon Japan Growth hormone deficiency; Diabetes Mellitus, Lipoatrophic; Dwarfism null 1994-10-05 Diabetes Mellitus, Lipoatrophic; Heart Failure; Myocardial Infarction; Multiple Sclerosis; HIV-Associated Lipodystrophy Syndrome; Dwarfism; Growth hormone deficiency Details
Mecasermin (Ipsen) FK-780; IGF-1; MKN-031; rhIGF-I (Ipsen) Approved Genentech Inc Increlex United States Failure to Thrive Ipsen Inc 2005-08-30 Failure to Thrive; Autism Spectrum Disorder; Phelan-McDermid syndrome; X-Linked Combined Immunodeficiency Diseases; Growth Disorders; Laron Syndrome Details
Brigatinib AP-26113 Approved Ariad Pharmaceuticals Inc Alunbrig, ALUNBRIG United States Carcinoma, Non-Small-Cell Lung Takeda Pharmaceuticals USA Inc 2017-04-28 Solid tumours; Ependymoma; Carcinoma; Neoplasms; Neurofibromatosis 2; Myofibroma; Lymphoma, Large-Cell, Anaplastic; Granuloma, Plasma Cell; Lung Neoplasms; Brain metastases; Carcinoma, Non-Small-Cell Lung; Sarcoma, Kaposi; Neurilemmoma; Neuroma, Acoustic; Meningioma Details
IGF-1 (Biogen/Pharmacia & Upjohn) Approved Biogen Inc, Pharmacia & Upjohn Igef Sweden Dwarfism null 1994-01-01 Dwarfism Details
Ceritinib LDK-378; NVP-LDK378; NVP-LDK378-NX Approved Novartis Pharma Ag 赞可达, Zykadia EU Carcinoma, Non-Small-Cell Lung Novartis Europharm Ltd 2014-04-29 Hepatic Insufficiency; Adenocarcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Brain metastases; Esophageal adenocarcinoma; Granuloma, Plasma Cell; Lymphoma, Large-Cell, Anaplastic; Thyroid Neoplasms; Hematologic Neoplasms; Colorectal Neoplasms; Cholangiocarcinoma; Neoplasms; Pancreatic Neoplasms; Glioblastoma; Thyroid Carcinoma, Anaplastic; Stomach Neoplasms Details
Teprotumumab R-1507; RG-1507; RO-4858696; HZN-001; RV-001(River Vision) Approved Genmab A/S, F. Hoffmann-La Roche Ltd Tepezza United States Graves Ophthalmopathy Horizon Therapeutics Ireland 2020-01-21 Neoplasms; Graves Ophthalmopathy; Breast Neoplasms; Sarcoma; Diabetic macular oedema; Scleroderma, Diffuse; Carcinoma, Non-Small-Cell Lung Details

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
Veligrotug ZB-001; VRDN-001; AVE-1642 Phase 3 Clinical Viridian Therapeutics Inc Solid tumours; Graves Ophthalmopathy; Multiple Myeloma; Breast Neoplasms Details
VRDN-003 VRDN-003 Phase 3 Clinical Viridian Therapeutics Inc Graves Ophthalmopathy Details
Ganitumab AMG-479 Phase 3 Clinical Amgen Inc Breast Neoplasms; Neuroectodermal Tumors, Primitive, Peripheral; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Lymphoma; Lung Neoplasms; Rhabdomyosarcoma, Alveolar; Colorectal Neoplasms; Neuroectodermal Tumors, Primitive; Sarcoma; Prostatic Neoplasms; Solid tumours; Sarcoma, Ewing; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Neoplasms; Carcinoid Tumor; Rhabdomyosarcoma, Embryonal; Ovarian Neoplasms; Intestinal Neoplasms; Bone metastases; Rhabdomyosarcoma Details
Linsitinib OSI-906; ASP-7487; OSI-906AA Phase 3 Clinical Astellas Pharma Inc, National Cancer Institute Multiple Myeloma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Paraganglioma; Mouth Neoplasms; Lip Neoplasms; Eye Diseases; Orbital Diseases; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Exophthalmos; Carcinoma, Basosquamous; Prostatic Neoplasms; Sarcoma, Ewing; Breast Neoplasms; Adrenocortical Carcinoma; Liver Neoplasms; Graves Ophthalmopathy; Endocrine System Diseases; Hormone-Resistant Prostate Neoplasms; Skin Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Neoplasms; Hashimoto Disease; Head and Neck Neoplasms; Ovarian Neoplasms; Chondrosarcoma; Thyroid Diseases; Solid tumours; Carney Complex Details
FPI-1434 [225Ac]-FPI-1434; FPX-01 Phase 2 Clinical Fusion Pharma Solid tumours; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Neoplasms; Adrenocortical Carcinoma; Uveal melanoma; Breast Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms Details
Dalotuzumab h7C-10; MK-0646; F-50-035 Phase 2 Clinical Pierre Fabre Group Solid tumours; Rectal Neoplasms; Pancreatic Neoplasms; Neoplasms; Multiple Myeloma; Neuroendocrine Tumors; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung Details
CT-102 CT-102 Phase 2 Clinical Hangzhou Tianlong Pharmaceutical Co Ltd, Institute Of Radiation And Radiation Medicine, Chinese Academy Of Military Medical Sciences Liver Neoplasms; Carcinoma, Hepatocellular Details
Mecasermin Rinfabate rhIGF-I/rhIGFBP-3; TAK-607; OHB-607; IGF-I/IGFBP-3; SHP-607; HGT-ROP-001 Phase 2 Clinical Insmed Noonan Syndrome; Failure to Thrive; Cerebral Intraventricular Hemorrhage; Lung Diseases; Myotonic Dystrophy; Bronchopulmonary Dysplasia; Retinopathy of Prematurity; Laron Syndrome Details
Insulin growth factor receptor type 1 antisense therapy (Imvax) IGV-001 Phase 2 Clinical Thomas Jefferson University Glioblastoma Details
MHB018A MHB 018A; MHB-018A Phase 2 Clinical Minghui Pharmaceutical (Hangzhou) Co Ltd Graves Ophthalmopathy Details
PHP-1003 PHP-1003; PHP1003 Phase 2 Clinical Suzhou Pulekang Pharmaceutical Technology Co Ltd Graves Ophthalmopathy Details
Lonigutamab VB-421 Phase 2 Clinical Pierre Fabre Group Graves Ophthalmopathy Details
Cixutumumab A-12; IMC-A12; LY-3012217; NSC-742460 Phase 2 Clinical Eli Lilly And Company Chondrosarcoma, Extraskeletal Myxoid; Pinealoma; Brain Stem Neoplasms; Gliosarcoma; Breast Neoplasms; Gastrinoma; Medullary thyroid cancer (MTC); Lymphoma, Mantle-Cell; Neuroblastoma; Adenocarcinoma, Bronchiolo-Alveolar; Osteosarcoma; Retinoblastoma; Neurofibrosarcoma; Sarcoma; Sarcoma, Ewing; Prostatic Neoplasms; Glucagonoma; Mesothelioma; Glioma; Adenocarcinoma; Melanoma; Paraganglioma; Carcinoma, Non-Small-Cell Lung; Breast Neoplasms, Male; Carcinoma, Hepatocellular; Neuroectodermal Tumors, Primitive, Peripheral; Carcinoma, Neuroendocrine; Neuroendocrine Tumors; Esophageal Squamous Cell Carcinoma; Hemangiopericytoma; Esophageal adenocarcinoma; Sarcoma, Alveolar Soft Part; Lung Neoplasms; Rhabdomyosarcoma, Alveolar; Metastatic breast cancer; Colorectal Neoplasms; Hepatoblastoma; Stomach Neoplasms; Mesenchymoma; Rectal Neoplasms; Carcinoma, Merkel Cell; Esophageal Neoplasms; Insulinoma; Squamous Cell Carcinoma of Head and Neck; Rhabdomyosarcoma, Embryonal; Carcinoma; Desmoplastic Small Round Cell Tumor; Hema Details
Picropodophyllin PPP; AXL-1717; NSC-36407 Phase 2 Clinical Axelar Ab Astrocytoma; Carcinoma, Non-Small-Cell Lung Details
NNC0268-0965 NNC0268-0965 Phase 1 Clinical Novo Nordisk A/S Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2 Details
IGF-1 receptor oligodeoxynucleotide-based immunotherapy (Thomas Jefferson University) Phase 1 Clinical Sidney Kimmel Cancer Center Glioma Details
Insulin-Like Growth Factor 1 (Wright State Physicians) Phase 1 Clinical Wright State Physicians Nasolabial fold wrinkles; Healthy Aging; Burns; Sunburn Details
SAR-446159 ABL-301; SAR-446159 Phase 1 Clinical Abl Bio Inc Parkinson Disease Details
VRDN-002 VRDN-002 Phase 1 Clinical Viridian Therapeutics Inc Graves Ophthalmopathy Details
LX-101 (Lirum Therapeutics) 765IGF-MTX; IGF/MTX Phase 1 Clinical Lirum Therapeutics Inc Head and Neck Neoplasms; Anemia, Refractory, with Excess of Blasts; Neoplasms; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Graves Ophthalmopathy; Brain Neoplasms; Breast Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Gastrointestinal Neoplasms; Melanoma Details
ZB-011 ZB-011; ZB011 Phase 1 Clinical Viridian Therapeutics Inc Graves Ophthalmopathy Details
Teprotumumab biosimilar(Boxiao Bio-pharma) Phase 1 Clinical Zhejiang Boxiao Bio-pharmaceutical Co Ltd Graves Ophthalmopathy Details
124I-CPD-1023-figitumumab 124I-CPD-1028; 125I-CPD-1028; CPD-1028-[124I]; CPD-1028-[125I]; FPX-1028 Phase 1 Clinical Fusion Pharma Neoplasms Details
ALTSuLIN Clinical Diabetes Mellitus, Type 1; Laron Syndrome Details

This web search service is supported by Google Inc.

totop